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Interferon-gamma as adjunctive immunotherapy
for invasive fungal infections: a case series
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Abstract
Background: Invasive fungal infections are very severe infections associated with high mortality rates, despite the
availability of new classes of antifungal agents. Based on pathophysiological mechanisms and limited pre-clinical
and clinical data, adjunctive immune-stimulatory therapy with interferon-gamma (IFN-γ) may represent a promising
candidate to improve outcome of invasive fungal infections by enhancing host defence mechanisms.
Methods: In this open-label, prospective case series, we describe eight patients with invasive Candida and/or
Aspergillus infections who were treated with recombinant IFN-γ (rIFN-γ, 100 μg s.c., thrice a week) for 2 weeks in
addition to standard antifungal therapy.
Results: Recombinant IFN-γ treatment in patients with invasive Candida and/or Aspergillus infections partially
restored immune function, as characterized by an increased HLA-DR expression in those patients with a baseline
expression below 50%, and an enhanced capacity of leukocytes from treated patients to produce proinflammatory
cytokines involved in antifungal defence.
Conclusions: The present study provides evidence that adjunctive immunotherapy with IFN-γ can restore immune
function in fungal sepsis patients, warranting future clinical studies to assess its potential clinical benefit.
Trial registration: ClinicalTrials.gov - NCT01270490
Keywords: Immunotherapy, Interferon-gamma, Candidemia, Aspergillosis
Background
The incidence of fungal infections is steadily increasing in
the last years due to invasive medical diagnosis and im-
munosuppressive treatment modalities. Despite develop-
ment of new classes of antifungal agents [1], the invasive
fungal infections remain associated with unacceptable
high mortality rates and represent a major cause of death
worldwide [2-7]. The emergence of significant resistance
to the currently available antifungal therapies emphasizes
the need for novel approaches to treat invasive fungal in-
fections [8,9]. Invasive fungal infection are most com-
monly observed in individuals with immune defects or a
compromised immune system, and the number of these
patients is steadily increasing [10]. Therefore, adjunctive
immunotherapy to improve host defence is an attractive
strategy to improve the outcome of patients with dissemi-
nated fungal infections.
In the past decade, major progress in the understand-
ing of anti-fungal host responses has enabled the devel-
opment of a number of novel molecular and cell-based
immunotherapeutic approaches for invasive fungal infec-
tions [11]. Although invasive candidiasis and aspergil-
losis are rather different in their pathogenesis, the major
protective host response against both fungi is the effect-
ive induction of Th1 and IFN-γ responses [12-16]. The
Th1 cytokine response activates effector phagocytic cells
that kill the fungus [17]. Interestingly, Th1 immunity
against A. fumigatus was demonstrated to be cross-
protective against C. albicans [18].
* Correspondence: mihai.netea@radboudumc.nl
†Equal contributors
1Department of Internal Medicine, Division of Experimental Internal Medicine,
Radboud University Medical Center, Nijmegen, The Netherlands
6Department of Internal Medicine (463), Radboud University Nijmegen
Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
Full list of author information is available at the end of the article
© 2014 Delsing et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Delsing et al. BMC Infectious Diseases 2014, 14:166
http://www.biomedcentral.com/1471-2334/14/166
Interferon-gamma (IFN-γ), the prototype Th1 cyto-
kine, promotes Th1 differentiation and skews the im-
mune response towards a protective Th1 phenotype
[19]. As such, it has been implicated as a treatment op-
tion in (invasive) fungal infections [20,21]. Moreover,
limited evidence suggests that recombinant IFN-γ
(rIFN-γ) has a beneficial effect on the outcome of fungal
infections in patients with chronic granulomatous dis-
ease (CGD) [22], HIV [23-25], leukemia [26,27], and in
patients receiving organ transplants [28]. However, it has
not been investigated whether rIFN-γ actually enhances
the immune response in these patients to explain these
beneficial clinical effects.
In this report we describe a series of patients with in-
vasive Candida and/or Aspergillus infections in whom
we investigated the effects of treatment with rIFN-γ on
the host innate and adaptive immune responses.
Methods
Patients and treatment
To assess the feasibility and preliminary efficacy of IFN-γ
in combination with anidulafungin for the treatment of
candidemia, a single-centre, prospective, randomized
open-label pilot (Phase IIIb) study was conducted. This
study was registered at ClinicalTrials.gov (NCT01270490)
and approved by the local ethics committee of the
Radboud University Medical Center. Due to slower than
anticipated enrollment rates (from August 2010 until
March 2013, only 12 patients could be screened, of which
6 were eligible and provided informed consent [Figure 1]),
the study was terminated early. However, during this
period, several other patients presented with invasive fun-
gal infections which had an insufficient response to stand-
ard antifungal therapy. Although these patients did not
meet the inclusion criteria (i.e. presenting with one or
more positive cultures of blood or normally sterile tissue
growing Candida spp.), they were deemed to benefit from
adjunctive immunotherapy as “therapy of last resort” as de-
cided by the attending physician. Within the parameters of
standard clinical care these patients were treated according
to the same protocol as the patients enrolled in the study,
and were therefore included in the present case series. All
patients with a history of documented epileptic seizures,
pre-existent severe renal impairment (creatinine clearance
<30/mL/min) or severe liver failure (defined as a spontan-
eously increased prothrombin time) were excluded. After
obtaining informed consent, eight patients (3 study pa-
tients, 5 last resort patients) were treated with rIFN-γ
(Immukine, Boehringer Ingelheim, 50 μg/m2 body surface,
subcutaneously, three times a week) in addition to standard
antifungal therapy as recommended by national and inter-
national treatment guidelines [29,30]. Three patients who
were included in the Phase IIIb Candida pilot-study were
assigned to the control group and did not receive rIFN-γ.
Blood sampling
Plasma, serum and whole blood specimens were col-
lected at baseline (BL) and serially after the start of anti-
fungal therapy (days 1, 2, 3, 7, 14 and 28). Blood cultures
were performed as part of routine care.
Leukocyte populations and surface HLA-DR expression
Heparin anticoagulated blood was stored at 4°C immedi-
ately after withdrawal and analyzed by flow cytometry.
To determine the extent of immune suppression, HLA-DR
expression was determined by calculating % HLA-
DR-positive cells and HLA-DR mean fluorescence intensity
(MFI) within CD14+ cells and various lymphocyte
subsets within CD45+ leukocytes+ (see Additional
file 1 and Additional file 2: Figure S1 for details and a
representative flow diagram). Lymphocyte subsets were
defined as: T-cells (CD45+CD3+), T-helper cells (Th,
CD45+CD3+CD4+), cytotoxic T-cells (Tc, CD45+CD3+
CD8+), B-cells (CD45+CD19+), and NK-cells (CD45+
CD3−CD56+). Subset counts were calculated by multi-
plying the percentage of gated cells by the total
lymphocyte count. Patients with <50% HLA-DR positive
monocytes at baseline were considered to exhibit im-
mune paralysis. This threshold of 50% is well below the
lower bound of the 99% confidence interval obtained in
healthy volunteers in an earlier study of our group using
the same methodology in the same laboratory [31].
Therefore mHLA-DR expression levels below 50% are
likely to represent immunoparalysis.
Cytokine assays
Venous blood was drawn into 10 mL EDTA tubes, after
which peripheral blood mononuclear cells (PBMCs)
were isolated as described previously [32]. In short,
blood was diluted in phosphate buffered saline (PBS)
(1:1) and fractions were separated by Ficoll (Ficoll-Paque
Plus, GE healthcare, Zeist, The Netherlands) density gra-
dient centrifugation. Cells were washed twice with PBS
and resuspended in RPMI-1640+ (RPMI-1640 Dutch
modification supplemented with 10 μg/mL gentamicin,
10 mM L-glutamine, and 10 mM pyruvate) (Gibco,
Invitrogen, Breda, The Netherlands). The PBMCs were
counted using a particle counter (Beckmann Coulter,
Woerden, The Netherlands) and were plated in 96 well
round-bottom plates (Corning, NY, USA) at a final con-
centration of 2,5×106/mL, in a total volume of 200 μL.
The PBMCs were stimulated for 24 hours, 48 hours, and
7 days with medium alone, or medium containing E. coli
lipopolysaccharide (LPS; 10 ng/mL), phytohaemaglutin-
nin (PHA; 10 μg/ml), heat-inactivated Candida albicans
blastoconidia (1×106/ml) or heat-inactivated Candida
albicans hyphae (derived from 1×106/m conidia). After
stimulation, cell culture supernatant was collected and
stored at −20°C. When all samples were collected,
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cytokines were measured using commercially available ELI-
SAs (R&D Systems, MN, USA and Sanquin, Amsterdam,
The Netherlands) according to the protocols supplied by
the manufacturer. Ex-vivo production of cytokines was
assessed at timepoints at which their production has been
shown to peak [33]. Monocyte derived cytokines such as
Interleukin (IL)-1β and tumour necrosis factor (TNF)α
were measured in culture supernatants of 24 hour cultures,
IL-10 was measured in culture supernatants of 48 hour
cultures. T-cell derived cytokines IL-17 and IL-22 were
measured in culture supernatants of 7 day cultures.
Statistical analysis
In view of the small sample size, normality of distribu-
tion was not assumed. Comparisons of baseline with
follow up time points were made using Wilcoxons
signed rank test (within-group comparisons, 2 groups).
A p-value of <0.05 was considered statistically significant.
Data are expressed as means and standard error of the
mean. Calculations and statistical analyses were performed
using GraphPad Prism v 5.0 (GraphPad Software, San
Diego, CA, USA).
Results
Patient characteristics
The patients treated with rIFN-γ (5 men, 3 women) had
a median age of 49.5 [IQR 28.5-68.8] years. The three
female patients in the control group were 36, 51 and
73 years old. Clinical characteristics of the participants
are listed in Table 1. Of the 6 patients included in the
pilot study, three patients had a positive blood culture
for C. albicans, two patients for C. glabrata, and one pa-
tient for C. tropicalis. During randomization, the three
patients with C. albicans cultures were assigned to rIFN-γ
treatment, whereas the two patients with C. glabrata
and one with C. tropicalis cultures were assigned to the
control group. However, no pathophysiological evidence
currently exists to suggest that rIFN-γ therapy would
have a different effect on the immune system in case
of albicans vs. non-albicans Candida infections. Of
the other 5 patients treated with rIFN-γ as therapy of
last resort, one patient had proven acute aspergillosis,
one had probable acute aspergillosis, and one probable
chronic aspergillosis according to the EORTC/MSG cri-
teria [34]. One patient had a positive blood culture for
C. tropicalis associated with osteomyelitis. This patient
developed new suspected lesions on positron emission
tomography-computed tomography (PET-CT) while re-
ceiving antifungal treatment. In another patient, CT-
scan revealed progression of suspected hepatic Candida
lesions during antifungal treatment. All patients in-
cluded suffered some degree of immunosuppression:
the 6 patients with positive blood cultures for Candida spp.
had impaired physical barriers due to the presence of
γ
γ
γ
12 patients were assessed for eligibility
7 patients met one or more exclusion
criteria, or did not provide informed
consent
6 patients were randomized
3 patients were assigned
to receive IFN-
3 patients were assigned
to receive placebo
3 patients were included
in the analysis at day 28
3 patients were included
in the analysis at day 28
5 patients who did not meet  the 
inclusion criteria were treated with
IFN- as “therapy of last resort”
In total, 11 patients were analyzed : 
3 study patients and  5 “last resort” 
patients received IFN-
5 patients were included
in the analysis at day 28
Figure 1 Screening, randomization, and follow-up of the study patients. The principal investigator was immediately notified when Candida
spp. were cultured in blood. With at least one systemic inflammatory response syndrome (SIRS) symptom present in the 24 hours prior to blood
culture withdrawal, and administration of systemic antifungal therapy < 72 hours, patients were deemed eligible for the ‘IFN-γ as an adjunctive
treatment for candidemia’ pilot-study. In addition, 5 patients not meeting inclusion criteria but who were also treated with rIFN-γ as a therapy of
last resort, were included in analysis.
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Table 1 Summary of clinical characteristics of all patients with invasive fungal infections
IFN-γ treated patients
Age Pathogens n= Site of nfection n= Underlying illness n= Antifungal therapy n= Outcome n=
49.6 ± SD19.8
C. albicans 3 Candidaemia 2 Stem cell transplantation for AML 1 Anidulafungin 1
Cured without further infectious
complications
2
BMI Candida spp 2 Candidaemia
Endocarditis
1
Sarcoidosis treated with prednisone
and azathioprin
1 Fluconazole 1
Lost to follow up after discharge
from hospital
1
22.9 ± SD6.9 A. fumigatus 2
Pulmonary
aspergilllosis
3
First remission induction chemotherapy
for AML
1 L-AMB + Voriconazole 1 Slight reduction hepatic lesions 1
Gender C. tropicalis 1 Osteomeyelitis 1 ICD, Streptococcus sanguis endocarditis,
aorta valve replacement with bioprosthesis
1
Voriconazole +
Anidulafungin
1
Cured but complicated with
mycotic cerebral aneurysms
1
F: 5 M: 3
A. fumigatus+
M. genavese
1 Hepatic abcess 1
persistent pulmonary cavity after radiotherapy
for a T1N0M0 lungcarcinoma
1
Itraconasole, L-AMB,
Voriconazole
1
Cured from candidemia episode,
4 months later unrelated bacterial
sepsis episode
1
Total parenteral nutrition via Hickmann catheter
because of slow transit bowel, intestinal pseudo
obstruction, or gastroparesis
3
Anidulafungin and step
down to fluconazol
3
Died due to infectious complications
71 or 15 days after initiation of
IFN-γ therapy
2
Placebo treated patients
53.0 ± SD19.1 C. glabrata 2 Candidaemia 3
Total parenteral nutrition via Hickmann
catheter because of slow transit bowel
1 Anidulafungin 2
Cured without further infectious
complications
3
BMI C. tropicalis 1 HIV with porth-a-cath for venous access 1 Anidulafungin +
amphotericin B
1
18.5 ± SD4.0
construction of ileal conduit urinary
diversion (Bricker deviation) because of
pT4N2M1 bladder cancer.
1
Gender
F: 3 M: 0
F, female; M, male; ICD, implantable cardioverter-defribillator; HIV, human immunodeficiency virus; L-AMB, liposomal amphotericin B; BAL, bronchoalveolar lavage; AML, acute myeloid leukemia.
D
elsing
et
al.BM
C
Infectious
D
iseases
2014,14:166
Page
4
of
12
http://w
w
w
.biom
edcentral.com
/1471-2334/14/166
indwelling venous catheters (for the need of recurrent
blood sampling or total parental nutrition), or an implant-
able cardioverter-defribillator (ICD) lead. The patient with
progression of suspected hepatic Candida lesions on the
CT-scan, and one patient with proven acute aspergillosis
(diagnosed by isolation of A. fumigatus from lung tissue
biopsies) were immunocompromised because of (therapy
for) acute myeloid leukaemia. Another patient with acute
invasive aspergillosis (A. fumigatus isolated from BAL
fluid) received immunosuppressive therapy (prednisone
and azathioprine) for sarcoidosis and suffered from a co-
infection with Mycobacterium genavense localized in the
bone marrow. A third patient developed chronic pulmon-
ary aspergillosis (diagnosed by consistent CT abnormal-
ities with cavitation and culture of A. fumigatus from BAL
fluid) after radiotherapy for lung carcinoma. Only two pa-
tients, both with acute aspergillosis, were admitted to the
Intensive Care Unit to receive organ supportive therapy
(mechanical ventilation and hemodynamic support).
Clinical outcome
The three patients in the control group and five out of
eight patients treated with rIFN-γ recovered unevent-
fully from the fungal infection (Table 1). Two patients
with invasive aspergillosis that were already admitted to
the ICU at the time of treatment died due to infectious
complications of severe pulmonary aspergillosis, despite
rIFN-γ treatment. The patient with a Candida endocar-
ditis, who despite rIFN-γ treatment developed intracere-
bral mycotic aneurysm, could be discharged from the
hospital 93 days after onset of invasive candidiasis.
In all patients treated, rIFN-γ was well tolerated. Five
patients reported moderate fever upon administration
of rIFN-γ, which responded well to acetaminophen.
Two patients developed liver enzyme abnormalities for
which tuberculostatic antibiotics and voriconazole were
temporarily discontinued, resulting in recovery of the
liver enzyme abnormalities while rIFN-γ treatment was
continued. No other significant adverse events were
observed.
Effect of rIFN-γ on ex-vivo IL-1β and TNFα production
To assess the effect of rIFN-γ on the capacity of
PBMCs to produce pro-inflammatory cytokines, cells
were isolated and stimulated before, during, and after
treatment. We monitored the fold change in cytokine
production compared with baseline (before start of treat-
ment). IL-1β and TNFα are pro-inflammatory cytokines of
the innate immune system crucial in the induction and
maintenance of the anti-fungal immune response [35-40].
Before IFN-γ treatment, inter-patient variability in cyto-
kine production was high (e.g. TNFα median [IQR] con-
centration after stimulation with LPS was 792 pg/mL
[314–2005]). Nevertheless, in all patients an increase in
the capacity to induce different cytokines was observed
in the first two days after initiation of IFN-γ treatment,
independent of their baseline values (group data shown
in Figure 2), at subsequent time points only a trend to-
wards increased could be observed. In contrast, the
placebo-treated patients IL-1β and TNFα responses over
time remained similar to baseline. The response against hy-
phae of C. albicans was highly variable between patients.
Some rIFN-γ-treated patients demonstrated a profound in-
crease of TNFα production after treatment (up to 70 fold),
whereas other patients showed no relevant change in
TNFα production. Cytokine production remained similar
in patients in the control group.
Effect of rIFN-γ on ex-vivo IL-17 and IL-22 production
Both IL-17 and IL-22 are cytokines that are thought to be
protective in the host defence against invasive fungal in-
fections [35,41-45]. PHA-induced IL-17 and IL-22 pro-
duction was increased 1 day after initiation of rIFN-γ
treatment (Figure 3). However, at subsequent time points
a trend towards increased IL-17 and IL-22 production
was observed, which reverted to baseline levels at day
28. Production of IL-17 and IL-22 upon stimulation
with Candida blastoconidia was elevated after rIFN-γ
treatment in 6 of 8 patients. Hyphae induced IL-17 and
IL-22 production was increased in 4 of 8 and 5 of 8 pa-
tients respectively. Patients who received placebo ther-
apy did not display a trend towards increased IL-17 or
IL-22 production during the course of treatment (group
data shown in Figure 3).
Effect of rIFN-γ on ex-vivo IL-10 production
In addition to pro-inflammatory cytokines, the capacity to
produce anti-inflammatory cytokines can also influence
disease outcome. In particular the anti-inflammatory cyto-
kine IL-10 has been associated with protection against im-
munopathology during severe infections. IL-10 production
in response to stimulation with LPS, PHA and Candida
was highly variable between patients and did not show a
distinct pattern following rIFN-γ treatment (Figure 4). No
relevant differences compared to the placebo-treated pa-
tients were observed.
HLA-DR expression
The numbers of HLA-DR-positive monocytes, a marker
of immunosuppression, varied substantially between pa-
tients at baseline (39.05% [27.5-61.6] vs. 90.6 [88.7-92.5]
in IFN-γ-treated patients and placebo-treated patients,
respectively). Five out of eight IFN-γ treated patients ex-
hibited HLA-DR positive monocyte levels below the
“immunoparalysis threshold” of 50% and in these pa-
tients, an increase of HLA-DR-positive monocytes after
IFN-γ treatment between 10% and 44% was observed
which persisted throughout the study period (Figure 5).
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Patients with a baseline HLA-DR expression higher than
50% did not show a change in expression. The patient
with a HLA-DR-expression <50% who did not show in-
creased levels of HLA-DR positive monocyte numbers at
any time point, was one of the two patients who died
due to infectious complications. No correlation was
found between the level of mHLA-DR expression and
TNFα production of LPS-stimulated PBMCs. An inverse
correlation of baseline mHLA-DR levels with severity of
underlying illness and tissue involvement was found
(with higher mHLA-DR levels in patients with only im-
paired physical barriers, e.g. due to indwelling catheters,
compared to patients with impaired immune responses,
e.g. due to chemotherapy, immune suppressive agents,
bone marrow disease; data not shown because this com-
promises patients anonymity).
Figure 2 Effect of rIFN-γ on ex-vivo IL-1β and TNFα production. PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after
rIFN-γ administration. Isolated PBMCs were stimulated for 24 hours with LPS, PHA, C. albicans blastoconidia, or C. albicans hyphae. IL-1β (A) and
TNFα (B) concentrations were measured in culture supernatants. Baseline concentrations were used as control and set at 1; subsequent
measurements are plotted as the mean relative fold change ± SEM. Significant change from baseline was determined by subjecting the data
to Wilcoxons signed rank test. (* = p < 0.05; ** = p < 0.01).
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Cell populations
There were no significant changes in the total leukocyte
and granulocyte numbers in rIFN-γ-treated patients
(Additional file 3: Figure S2A). Monocyte counts signifi-
cantly increased one week after initiation of rIFN-γ ther-
apy (Additional file 3: Figure S2C) and lymphocyte
numbers significantly increased at 2 and 7 days after ini-
tiation of rIFN-γ therapy (Additional file 3: Figure S2D),
which could be attributed to slight changes in CD4 lym-
phocytes (Additional file 3: Figure S2E), B-lymphocyte
(Additional file 3: Figure S2F) and NK-cell numbers
(Additional file 3: Figure S2G) and a significant increase
of CD8 lymphocytes (Additional file 3: Figure S2H). No
clear changes in leukocyte (subset) counts were observed
in placebo-treated patients.
Discussion and conclusions
While several small clinical trials illustrated the benefi-
cial clinical effects of adjuvant treatment with IFN-y, the
proposed immunostimulating effect of IFN-γ as the
mechanism of action has not been investigated. In this
case series we demonstrate for the first time that ad-
junctive immunotherapy with rIFN-γ improves the
leukocyte immune responses in patients with severe in-
vasive fungal infections. This was primarily reflected by
increased ex-vivo pro-inflammatory cytokine responses
of the innate immune system such as IL-1β or TNFα, as
well as an increased production of the T-cell cytokines
IL-17 and IL-22, which are known to play an important
role in the anti-fungal host defence [35,41-45], and
by an increase in HLA-DR expression in mHLA-DR
Figure 3 Effect of rIFN-γ on ex-vivo IL-17 and IL-22 production. PBMCs of patients were isolated at baseline and day 1, 2, 7, 14 and 28 after
rIFN-γ administration. Isolated PBMCs were stimulated for 7 days with PHA, C. albicans blastoconidia, or C. albicans hyphae. IL-17 (A) and IL-22 (B)
concentrations were measured in culture supernatants. Baseline concentrations were used as control and set at 1; subsequent measurements are
plotted as the mean relative fold change ± SEM. Significant change from baseline was determined by subjecting the data to Wilcoxons signed
rank test. (* = p < 0.05).
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expression in those patients with a low cellular expres-
sion as a measure of their immune suppression.
In addition to enhanced ex-vivo responses, subtle
changes in the leukocyte differentiation were observed
following IFN-γ treatment. Although there were no sig-
nificant differences in total leukocyte numbers after
treatment with rIFN-γ, shifts in leukocyte subpopula-
tions such as increased monocyte and lymphocyte
counts were apparent. While lymphocyte numbers in-
creased after rIFN-γ therapy, it could not directly be at-
tributed to a specific subset as all of them showed
increased values. The most significant increase was that
of CD8 cells one week after initiation of rIFN-γ therapy.
Monocytes and lymphocytes are known to be crucial
cells in the host defence against fungal infections.
However, the increase of monocytes and lymphocytes
during rIFN-γ therapy was accompanied by slightly
decreased circulating granulocyte numbers. It is not
known whether this reduction is due to activation and
migration into the infected tissue, or whether a true de-
crease in granulocyte generation was induced by the
treatment. Although the decrease in granulocyte num-
bers was slight, the fact that granulocytes, and espe-
cially neutrophils, are crucial in the antifungal host
defence warrant careful monitoring of granulocyte
numbers during IFN-γ treatment.
Several clinical studies and case reports have previ-
ously demonstrated beneficial effects of rIFN-γ in com-
bination with antifungal therapy on outcome of fungal
infections (for example in patients with CGD (n = 130)
[22,46,47], HIV (n = 173) [23-25], leukaemia (n = 5)
[26,27], and transplant patients (n = 7) [28], in a patient
with S. aureus liver abscess and invasive C. albicans in-
fection [48], in a patient with intracerebral aspergillosis
[49], in two patients with progressive chronic pulmonary
aspergillosis [50], and in two patients with idiopathic
CD4 lymphopenia and cryptococcal meningitis [51]).
However, in contrast to our study, ex-vivo immune re-
sponses in these patients were not investigated. Due to
the limited number of patients and the very heteroge-
neous population, we could not assess clinical endpoints,
although a mean mortality of 25% in the IFN-γ treated
patients lies below the mean 40% estimated in patients
with invasive fungal infections [10,52].
To the best of our knowledge, we are the first to de-
scribe mHLA-DR expression, a widely used marker of
Figure 4 Effect of rIFN-γ on ex-vivo IL-10 production. PBMCs of
patients were isolated at baseline and day 1, 2, 7, 14 and 28 after
rIFN-γ administration. Isolated PBMCs were stimulated for 48 hours
with LPS, PHA, C. albicans blastoconidia, or C. albicans hyphae. IL-10
concentrations were measured in culture supernatants. Baseline
concentrations were used as control and set at 1; subsequent
measurements are plotted as the mean relative fold change ± SEM.
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immunosuppression in (bacterial) sepsis patients [53], in
patients with invasive fungal infections. In all IFN-γ
treated patients who showed baseline mHLA-DR levels
below the immunoparalysis threshold of 50% and sur-
vived, IFN-γ mediated upregulation of mHLA-DR ex-
pression was observed. In agreement with the data
presented in this case series, rIFN-γ has been shown
to significantly increase numbers of HLA-DR-positive
monocytes both in a human preclinical bacterial sepsis
model and in septic patients [31,54]. Reduced produc-
tion of TNFα by leukocytes ex-vivo stimulated with LPS
has also been shown to be marker of immunoparalysis
in sepsis patients. In contrast to our study, mHLA-DR
expression and ex-vivo TNFα production were found to
be highly correlated in bacterial sepsis patients [54,55].
A possible explanation for this discrepancy is that, in
contrast with the emerging consensus that immunopara-
lysis renders patients more vulnerable to opportunistic
infections in general [53], different defects in immune
defences may be responsible for enhanced susceptibility
towards different pathogens.
Based on the apparent inverse correlation of baseline
mHLA-DR levels with severity of underlying illness and
tissue involvement, mHLA-DR levels seem to reflect
disease severity and general immune status, and not
specific immune defects per se. Hence, patients with
invasive fungal infections and associated impaired anti-
fungal immune responses will probably benefit more
from immunostimulatory treatment compared to pa-
tients with only impaired physical barriers, e.g. due to
indwelling catheters and apparent intact anti-fungal
immune responses. Biomarkers reflecting the capacity of
specific anti-fungal immune defences are required to
identify patients who suffer from invasive fungal infec-
tions due to impaired cell-mediated immunity. It is im-
portant to identify such patients and attempt a tailored
immunotherapeutic approach guided by the actual level
and type of immunoparalysis of that specific patient. A
blood based assay has been described that demonstrates a
failure to induce IFN-γ expression in renal transplant pa-
tients and differences in IL-10 and TNFα expression [56],
which could be promising biomarkers to identify patients
who could benefit from adjunctive immunotherapy.
The intracellular mechanism(s) through which the
beneficial effects of IFN-γ are mediated remain to be elu-
cidated. Recently it was proposed that IFN-γ exerts its ef-
fects at the transcription level [57], while others have
demonstrated that IFN-γ reverses tolerance-associated
epigenetic modifications [58]. Another possible mechan-
ism involved in the IFN-γ mediated reversal of immuno-
paralysis is the downregulation of negative TLR regulators
such as IRAK-M, a protein that negatively regulates LPS-
induced inflammatory responses and contributes to the
development of immunoparalysis [59].
Administration of rIFN-γ was tolerated well. Several
patients developed a mild fever upon administration,
which responded well to acetaminophen treatment. No
other side effects were observed. The most important
limitation of the present study is the limited number of
patients studied. Because the control group consisted of
only three patients, no statistical analysis between the
treatment and control groups could be performed. How-
ever, despite the small sample size, the increase in HLA-
DR expression in patients with mHLA-DR expression
levels below 50% and the increased ex-vivo response
of several cytokines that are crucial in antifungal host
defence is a promising observation that underlines the
potential of immunotherapy. The slow enrolment of pa-
tients presenting with candidemia was the main factor
contributing to the decision to terminate the phase IIIb
Candida pilot-study early. With a reported incidence of
2.5-11 per 100,000 persons in Europe [60], and based on
previous epidemiological data in our hospital this low
enrollment was not expected at the time of the initiation
of the study. The much lower incidence of candidemia
in the last two years in our hospital is most likely due to
a new antibiotic stewardship introduced recently in our
hospital, which has reduced the incidence of opportunis-
tic infections. The cut-off value of mHLA-DR expression
levels of 50% to distinguish between immunoparalyzed
and immunocompetent patients is another limitation of
this study, as this is an arbitrary value chosen. We chose
this value because it is well below the 99% CI of mHLA-
DR values in healthy volunteers [31]. Therefore, patients
with mHLA-DR below 50% do have an impaired antigen
Figure 5 mHLA-DR expression in rIFN-γ treated patients,
divided into immunoparalyzed patients with baseline HLA-DR
expression below 50% (solid dots), and without HLA-DR defined
immunoparalysis (open dots). Data are expressed as median [IQR].
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presenting capacity of their monocytes which we show
to be enhanced by IFN-γ therapy. Whether this cut-off
value truly represents immunoparalysis, reflected by en-
hanced susceptibility to secondary infections or reduced
capacity to clear opportunistic infections, remains to
be investigated. Furthermore, the use of a standardized
analysis technique to quantify mHLA-DR, such as the
Quantibrite method, is preferable, because it facilitates an
objective comparison of mHLA-DR expression levels be-
tween studies and aids in the definitive establishment of a
cut-off value to identify immunoparalyzed patients. Larger
studies are required to confirm the data obtained here. To
do so, multicentre studies should be facilitated in order to
fully explore the potential of IFN-γ immunotherapy.
Our data indicate that adjunctive immunotherapy with
rIFN-γ in patients with invasive fungal infections par-
tially restores cell-mediated immunity. This suggests that
IFN-γ treatment enhances anti-fungal immunity and lar-
ger studies are warranted to validate the findings re-
ported here and to assess the impact of IFN-γ treatment
on clinical outcome. Biomarkers of impaired anti-fungal
immunity should be further investigated in order to
identify patients who will benefit most from immunosti-
mulatory therapy.
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